StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report issued on Tuesday. The firm set a “sell” rating on the medical technology company’s stock.

Several other analysts have also issued reports on BIOL. Benchmark restated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets cut their target price on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd.

BIOLASE Price Performance

NASDAQ:BIOL opened at $0.01 on Tuesday. The company’s 50-day moving average is $0.03 and its two-hundred day moving average is $0.08. The firm has a market capitalization of $167,035.00, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94.

Institutional Investors Weigh In On BIOLASE

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC increased its position in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the period. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent quarter. 8.79% of the stock is owned by hedge funds and other institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.